drugset / Trial / NCT06344156
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Neoantigen Vaccines | Vaccine | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |